PHVS|Pharvaris NV|Price:29.620|Chg%:-1.08

More Details of Pharvaris NV Company

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Pharvaris NV Info



Ticker SymbolPHVS

Company namePharvaris NV

IPO dateFeb 05, 2021

CEOModig (Berndt B.A.E)

Number of employees- -

Security typeOrdinary Share

Fiscal year-endFeb 05

AddressEmmy Noetherweg 2

CityLEIDEN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryNetherlands

Postal code2333 BK

Phone31712036410

Websitehttps://pharvaris.com/

Ticker SymbolPHVS

IPO dateFeb 05, 2021

CEOModig (Berndt B.A.E)

Company Executives of Pharvaris NV



Name

Name/Position

Position

Shareholding

Change

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

1.63M

-1.57%

Dr. Peng Lu, M.D., Ph.D.

Chief Medical Officer

505.84K

--

Mr. David W. Nassif, J.D.

Chief Financial Officer

201.62K

+99.60%

Dr. David P. Meeker ,M.D.

Non-Executive Director

152.35K

+32.51%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

110.78K

+54.39%

Ms. Viviane Monges

Non-Executive Director

106.11K

+48.26%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.28K

-5.73%

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

--

Dr. Anne Lesage, Ph.D.

Co-Founder, Chief Early Development Officer

--

Dr. Morgan Conn, Ph.D.

Chief Business Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

1.63M

-1.57%

Dr. Peng Lu, M.D., Ph.D.

Chief Medical Officer

505.84K

--

Mr. David W. Nassif, J.D.

Chief Financial Officer

201.62K

+99.60%

Dr. David P. Meeker ,M.D.

Non-Executive Director

152.35K

+32.51%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

110.78K

+54.39%

Ms. Viviane Monges

Non-Executive Director

106.11K

+48.26%

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Thu, Feb 19

Shareholders

Shareholder Types

Shareholders

Proportion

General Atlantic LLC

11.53%

Fidelity Management & Research Company LLC

9.19%

Foresite Capital Management, LLC

6.86%

VenBio Partners LLC

6.66%

Viking Global Investors LP

5.24%

Other

60.52%

Shareholders

Proportion

General Atlantic LLC

11.53%

Fidelity Management & Research Company LLC

9.19%

Foresite Capital Management, LLC

6.86%

VenBio Partners LLC

6.66%

Viking Global Investors LP

5.24%

Other

60.52%

Shareholder Types

Shareholders

Proportion

Private Equity

31.30%

Hedge Fund

20.13%

Investment Advisor

18.48%

Investment Advisor/Hedge Fund

10.17%

Venture Capital

4.94%

Individual Investor

4.89%

Research Firm

0.63%

Pension Fund

0.07%

Bank and Trust

0.07%

Other

9.33%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

165

59.26M

90.60%

-451.33K

2025Q4

152

61.74M

96.38%

+11.01M

2025Q3

118

49.64M

77.50%

-950.63K

2025Q2

125

52.21M

81.51%

-1.38M

2025Q1

125

53.89M

99.06%

+200.61K

2024Q4

123

53.45M

98.98%

+218.03K

2024Q3

114

53.86M

99.73%

+1.03M

2024Q2

83

52.08M

96.43%

-141.66K

2024Q1

76

49.63M

98.30%

-831.88K

2023Q4

69

47.76M

94.74%

+8.60M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

General Atlantic LLC

8.03M

12.54%

--

Dec 31, 2025

Fidelity Management & Research Company LLC

6.40M

9.99%

--

Dec 31, 2025

Foresite Capital Management, LLC

4.78M

7.46%

--

Dec 31, 2025

VenBio Partners LLC

4.64M

7.24%

--

Dec 31, 2025

Viking Global Investors LP

3.65M

5.7%

--

Dec 31, 2025

EQT Partners AB

3.42M

5.35%

--

Dec 31, 2025

Deerfield Management Company, L.P.

3.13M

4.88%

+683.58K

+27.99%

Dec 31, 2025

Bain Capital Life Sciences Investors, LLC

2.80M

4.37%

-379.19K

-11.92%

Dec 31, 2025

Wellington Management Company, LLP

1.91M

2.98%

+171.05K

+9.86%

Dec 31, 2025

Commodore Capital LP

1.89M

2.95%

-529.03K

-21.87%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Virtus LifeSci Biotech Clinical Trials ETF

0.87%

ALPS Medical Breakthroughs ETF

0.59%

iShares MSCI Netherlands ETF

0.23%

SPDR S&P International Small Cap ETF

0.08%

iShares MSCI Europe Small-Cap ETF

0.04%

iShares MSCI EAFE Small-Cap ETF

0.02%

Fidelity Nasdaq Composite Index ETF

0.01%

Xtrackers MSCI Eurozone Hedged Eqty ETF

0.01%

Avantis International Small Cap Equity ETF

0%

First Trust IPOX Europe Equity Opportunities ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0.87%

ALPS Medical Breakthroughs ETF

Proportion0.59%

iShares MSCI Netherlands ETF

Proportion0.23%

SPDR S&P International Small Cap ETF

Proportion0.08%

iShares MSCI Europe Small-Cap ETF

Proportion0.04%

iShares MSCI EAFE Small-Cap ETF

Proportion0.02%

Fidelity Nasdaq Composite Index ETF

Proportion0.01%

Xtrackers MSCI Eurozone Hedged Eqty ETF

Proportion0.01%

Avantis International Small Cap Equity ETF

Proportion0%

First Trust IPOX Europe Equity Opportunities ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data